Fundz

Immunome Inc. reported raising $5.06 Million in an initial SEC Form D filing, from an offering of $12 Million

PUBLIC · IMNMJul 14, 2016$5.1M of $12M raised

Amount Raised

$5.06 Million

$5.06 Million sold, per SEC Form D (first sale Jul 14, 2016)

Round Type

Venture

BothellBiotechnologyHealth CareMedicalTherapeutics

Who else raised in Medical and Therapeutics around the same time

Companies in the same sectors as Immunome Inc. that raised within 45 days of this round, from Fundz verified event records.

  • ELIAS Animal Health, LLC raised $650K (Seed) on July 7, 2016.
  • Rapport raised $845K (Seed) on August 24, 2016.
  • Amylyx Pharmaceuticals raised $4.1M (Seed) on August 22, 2016.
  • Fate Therapeutics raised $10M on August 19, 2016.
  • Femasys raised $3.3M on August 11, 2016.
  • AEON Biopharma raised $5.5M on August 10, 2016.

Who to call at Immunome Inc., and when

A new round usually means Immunome Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Immunome Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Immunome Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Immunome Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Immunome Inc.

Location

665 STOCKTON DRIVE

Bothell, Washington, United States

About

Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and antibody drug conjugates (ADCs). We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets. Immunome is proud to be an Equal Employment Opportunity employer. We do not discriminate based upon race, religion, color, national origin, gender (including pregnancy, childbirth, or related medical conditions), sexual orientation, gender identity, gender expression, age, status as a protected veteran, status as an individual with a disability, or other applicable legally protected characteristics.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Immunome Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contacts51 people are listed at Immunome Inc.. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Immunome Inc.'s next move

See what Strategic adds

Immunome Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.